Reuters logo
BRIEF-U.S. FDA provides new drug safety communication on Takeda's gout drug
November 15, 2017 / 6:33 PM / a month ago

BRIEF-U.S. FDA provides new drug safety communication on Takeda's gout drug

Nov 15 (Reuters) - U.S. Food and Drug Administration :

* U.S. FDA says preliminary results from a safety clinical trial show increased risk of heart-related death with Febuxostat (Uloric) versus Allopurinol

* U.S. FDA says once final results from Takeda Pharma are received in relation to safety clinical trial of Uloric, will conduct a comprehensive review Source text : (bit.ly/2iZYe1h) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below